GlassScriptPhysician profile
Andrew Gabor Kovacs
NPI 1598715880
$6,070.38
in general payments reported to CMS, 2019-2025
39 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $487 · 2021: $1,088 · 2022: $990 · 2023: $745 · 2024: $509 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,277.43 | 2021-2025 | |
| Ucb, INC. | $788.96 | 2019-2024 | Rystiggo |
| Ge Healthcare | $431.15 | 2021-2025 | |
| Biogen, INC. | $379.88 | 2020-2025 | Vumerity, Tysabri, Skyclarys |
| Novartis Pharmaceuticals Corporation | $348.73 | 2019-2025 | |
| Penumbra, INC. | $336.49 | 2022 | |
| Pfizer INC. | $272.59 | 2023-2025 | |
| Argenx US, INC. | $204.38 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $173.02 | 2021-2025 | |
| Kyowa Kirin, INC. | $173.01 | 2019-2022 | |
| Celgene Corporation | $161.14 | 2025 | Zeposia |
| Allergan, INC. | $154.59 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $145.89 | 2021-2025 | Wainua |
| Boston Scientific Corporation | $145.55 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $128.23 | 2019-2025 | Austedo, Austedo Xr |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kovacs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.